Is the LPA rs3798220 CT genotype linked to higher lipoprotein(a) and atherosclerotic risk?

Lipoprotein(a) [Lp(a)] is an independent, highly atherogenic particle whose circulating concentration is heavily dictated by genetics, notably the LPA gene variant rs3798220.

Genetic driver of elevated Lp(a)

• Carriers of the heterozygous LPA rs3798220 CT genotype (a nonsynonymous I4399M substitution in the protease-like domain) exhibit a 2- to 8-fold increase in circulating Lp(a) compared to TT non-carriers.
• This variant accounts for approximately 8% of Lp(a) population variance and is enriched on smaller apolipoprotein(a) [apo(a)] isoforms with fewer kringle IV type 2 repeats, ultimately doubling downstream coronary risk.

Mechanistic pathways to vascular disease

• Lipid deposition: The LDL-like core of Lp(a), containing apolipoprotein B-100, delivers cholesterol directly to the arterial wall, initiating cholesterol deposition, foam cell formation, and plaque development.
• OxPL-driven inflammation: Lp(a) serves as the primary plasma vehicle for oxidized phospholipids (OxPL), carrying 85% to 90% of circulating OxPL. These act as danger-associated molecular patterns (DAMPs) that trigger arterial wall inflammation, macrophage activation, and the osteogenic differentiation of valve interstitial cells, which drives calcific aortic valve disease.
• Prothrombotic biology: Due to high structural homology with plasminogen, apo(a) competitively inhibits fibrinolysis, dampening t-PA-mediated plasmin generation and Glu-to-Lys conversion to yield dense fibrin networks. Concurrently, OxPL-driven tissue factor expression and platelet activation favor coagulation.

Bottom line

• The LPA rs3798220 CT genotype genetically escalates circulating Lp(a) by 2- to 8-fold, promoting severe cardiovascular risk through a synergistic triad of LDL-like atherogenesis, intense OxPL-mediated inflammation, and apo(a)-mediated antifibrinolytic activity.